Lv1
55 积分 2021-10-18 加入
Treatment advances across the cervical cancer spectrum
3天前
已完结
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
4天前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
4天前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
4天前
已完结
Selective Elimination of Breast Surgery for Invasive Breast Cancer
4天前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
4天前
已完结
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
22天前
已完结
CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression
27天前
已关闭
Response to the Letter to the Editor on “CNS Outcomes of Osimertinib Plus Chemotherapy in Patients with EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression”
27天前
已关闭
Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases
27天前
已完结
皖公网安备34019202002308
